drugset
drugset / Trial / NCT01522586

Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of DWP09031

NCT01522586 ↗

Phase 1 Terminated 74 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedSingle-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of orally administrated DWP09031 in healthy male volunteers.

Timeline

Start
2012-01
Primary completion
2013-05
Completion
2013-12

Outcome

Outcome not reported

Stopped (Business): “change development strategy”

Drugs

EvaluationDrugModalityDoseRoute
Subject DWP09031 Unknown 50 mg Oral
Subject DWP09031 Unknown 100 mg Oral
Subject DWP09031 Unknown 200 mg Oral
Subject DWP09031 Unknown 400 mg Oral
Subject DWP09031 Unknown 800 mg Oral
Subject DWP09031 Unknown 1200 mg Oral
Subject DWP09031 Unknown 1600 mg Oral
Subject DWP09031 Unknown 2000 mg Oral

Indications

No indication recorded.